Translational Molecular Imaging of Prostate Cancer

Current Radiology Reports

Volumn 1, Issue 3, 2013, Pages 216-226

  Kiess, Ana P ^a   Cho, Steve Y ^a   Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Magnetic resonance imaging; Molecular imaging; Positron emission tomography; Prostate cancer; Prostate specific membrane antigen; Single photon emission computed tomography

Indexed keywords

EID: 85011082777     PISSN: None     EISSN: 21674825     Source Type: Journal    
DOI: 10.1007/s40134-013-0020-1     Document Type: Review

References (95)

1. American Cancer Society. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012.
2. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.
3. National Comprehensive Cancer Network. Prostate cancer clinical practice guidelines (version 2.2013). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 28 May 2013.
4. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31.
5. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA, J Am Med Assoc. 2010;304(21):2373–80.
6. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.
7. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.
8. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
9. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.
11. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.
12. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4(127):127.
13. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243(1):28–53.
14. Cho SY, Pomper MG. Molecular imaging in prostate cancer. In: Pomper MG, Gelovani JG, editors. Molecular imaging in oncology. New York: Informa Healthcare; 2008.
15. Shinohara K, Wheeler TM, Scardino PT. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol. 1989;142(1):76–82.
16. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59(6):962–77.
17. Bonekamp D, Jacobs MA, El-Khouli R, et al. Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics. 2011;31(3):677–703.
18. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol. 2007;63(3):351–60.
19. Vargas HA, Akin O, Afag A, et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol. 2012;188(5):1732–8.
20. Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol. 2011;21(9):1970–8.
21. 18 F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97.
22. Helyar V, Mohan HK, Barwick T, et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37(4):706–13.
23. Dennis ER, Jia X, Mezheritskiy IS, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30(5):519–24.
24. Ulmert D, Kaboteh R, Fox JJ, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012;62(1):78–84.
25. Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol. 2012;199(5):1114–20.
26. Fox JJ, Schoder H, Larson SM. Molecular imaging of prostate cancer. Curr Opin Urol. 2012;22(4):320–7.
27. 18 F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int. 2003;70(4):311–5.
28. 18 F]Fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11(13):4761–9.
29. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11(9):3210–6.
30. 99m Tc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16(24):6093–9.
31. Deb N, Goris M, Trisler K, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res. 1996;2(8):1289–97.
32. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21(9):1715–21.
33. 111 indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol. 2004;172(1):133–6.
34. 18 F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15(1):45–55.
35. Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer. Biochim Biophys Acta. 2013. doi:10.1016/j.bbalip.2013.03.010.
36. 11 C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res. 2011;17(24):7673–83.
37. 18 F]dOC). Nucl Med Biol. 2004;31(7):851–8.
38. 11 C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008;49(2):327–34.
39. 11 C-choline PET/CT images, showing the potential for false positives in prostatitis and BPH and false negatives in small (<5 mm) or necrotic tumors.
40. 11 C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50(9):1394–400.
41. Picchio M, Castellucci P. Clinical indications of C-choline PET/CT in prostate cancer patients with biochemical relapse. Theranostics. 2012;2(3):313–7.
42. Castellucci P, Fuccio C, Rubello D, et al. Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38(1):55–63.
43. 11 C]choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39(1):13–26.
44. 11 C-choline for detecting aggressive recurrent disease.
45. Souvatzoglou M, Krause BJ, Purschel A, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99(2):193–200.
46. 11 C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60(5):935–43.
47. 11 C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44(4):549–55.
48. Albrecht S, Buchegger F, Soloviev D, et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging. 2007;34(2):185–96.
49. 11 C]choline PET for detection of metastases of prostate cancer. Nucl Med. 2003;42(1):25–30.
50. Schuster DM, Taleghani PA, Nieh PT, et al. Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F]-fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. Am J Nucl Med Mol Imaging. 2013;3(1):85–96.
51. Amzat R, Taleghani PA, Savir-Baruch B, et al. Unusual presentations of metastatic prostate carcinoma as detected by anti-3 F-18 FACBC PET/CT. Clin Nucl Med. 2011;36(9):800–2.
52. 18 F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48(1):56–63.
53. 11 C-methionine positron emission tomography. J Urol. 2005;173(1):66–9 (discussion 69).
54. 18 F-FDG-PET/CT. Ann Nucl Med. 2012;26(2):138–45.
55. Rajagopalan KN, DeBerardinis RJ. Role of glutamine in cancer: therapeutic and imaging implications. J Nucl Med. 2011;52(7):1005–8.
56. 18 F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005;32(1):15–22.
57. 18 F-FMAU) in prostate cancer: initial preclinical observations. Mol Imaging. 2012;11(5):426–32.
58. Oyama N, Hasegawa Y, Kiyono Y, et al. Early response assessment in prostate carcinoma by (1)(8)F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models. Eur J Nucl Med Mol Imaging. 2011;38(1):81–9.
59. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32(3):344–50.
60. 18 F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45(3):366–73.
61. 18 F-FDHT PET imaging showing decreased binding after 4 weeks of enzalutamide therapy. This demonstrates the utility of molecular imaging for drug development and assessing individual treatment response.
62. Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology. 2001;57(6):1179–83.
63. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38(5):696–701.
64. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.
65. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170(5):1717–21.
66. 177 lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591–601.
67. Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2522–31.
68. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–7.
69. 89 Zr-DFO-J591 showed excellent tumor uptake and retention in LNCaP xenografts.
70. 64 Cu-J591 PET to quantitatively measure PSMA expression, showing that PSMA is upregulated by antiandrogen therapy. This provides an important proof of principle for using molecular imaging as a biomarker of receptor signaling.
71. 89 Zr-7E11 immuno-PET. J Nucl Med. 2011;52(10):1608–15.
72. Elsasser-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med. 2009;50(4):606–11.
73. Foss CA, Mease RC, Cho SY, et al. GCPII imaging and cancer. Curr Med Chem. 2011;19(9):1346–59.
74. Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13(8):951–62.
75. 99m Tc bone scan.
76. 18 F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17(24):7645–53.
77. Osborne JR, Hassan N, Vallabhajosula S, et al. Tc-99 m labeled small molecule inhibitors of prostate specific membrane antigen (PSMA): new molecular imaging probes to detect metastatic prostate adenocarcinoma. Chicago: American Society of Clinical Oncology; 2012.
78. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51(15):4504–17.
79. 18 F-FECH. Eur J Nucl Med Mol Imaging. 2012;39(6):1085–6.
80. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2012;40(4):486–95.
81. Chen Y, Pullambhatla M, Banerjee SR, et al. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem. 2012;23(12):2377–85.
82. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491–9.
83. Heesakkers RA, Hovels AM, Jager GJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9(9):850–6.
84. Ulmert D, Evans MJ, Holland JP, et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012;2(4):320–7.
85. 111 In-DOTA-ZIGF1R:4551. J Nucl Med. 2012;53(1):90–7.
86. Yu Z, Carlucci G, Ananias HJ, et al. Evaluation of a technetium-99 m labeled bombesin homodimer for GRPR imaging in prostate cancer. Amino Acids. 2012;44(2):543–53.
87. Zhang K, Aruva MR, Shanthly N, et al. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med. 2008;49(1):112–21.
88. Hall MA, Pinkston KL, Wilganowski N, et al. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF. J Nucl Med. 2012;53(9):1427–37.
89. Counsell RE, Schwendner SW, Meyer KL, et al. Tumor visualization with a radioiodinated phospholipid ether. J Nucl Med. 1990;31(3):332–6.
90. Pinchuk AN, Rampy MA, Longino MA, et al. Synthesis and structure–activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues. J Med Chem. 2006;49(7):2155–65.
91. Ghosh D, Lee Y, Thomas S, et al. M13-templated magnetic nanoparticles for targeted in vivo imaging of prostate cancer. Nat Nanotechnol. 2012;7(10):677–82.
92. Wu X, Burden-Gulley SM, Yu GP, et al. Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer. Bioconjug Chem. 2012;23(8):1548–56.
93. Chen AP, Albers MJ, Cunningham CH, et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med. 2007;58(6):1099–106.
94. 13 C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68(20):8607–15.
95. Yaligar J, Thakur SB, Bokacheva L, et al. Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness. NMR Biomed. 2012;25(1):113–22.